Search Results

Escient Pharmaceuticals announced that the first subject has been dosed in CALM-CSU, a Phase 2 clinical proof-of-concept study of EP262 in subjects with chronic spontaneous urticaria.

Escient Pharmaceuticals, a clinical-stage drug development company advancing novel small molecule therapeutics for systemic neuro-immune disorders, today announced that the first subject has been dosed in EASE, a Phase 2a clinical proof-of-concept study of EP262 in subjects with atopic dermatitis (AD).

Escient Pharmaceuticals announced that the first subject has been dosed in CALM-CIndU, an open label Phase 1b clinical proof-of-concept study of EP262 in subjects with chronic inducible urticaria.

Sana Biotechnology, Inc. announced the U.S. Food and Drug Administration has cleared the company’s Investigational New Drug application to initiate a study of SC262 in patients with relapsed or refractory B-cell malignancies, initially in patients who have received prior CD19-directed CAR T therapy.

Escient Pharmaceuticals today announced the presentation of preclinical data in multiple models of mast cell degranulation related to the company’s EP262 development program at the European Academy of Allergy and Clinical Immunology annual meeting being held in Hamburg, Germany, June 9-11, 2023.

Escient Pharmaceuticals, a clinical-stage drug development company advancing novel small molecule therapeutics for systemic neuro-inflammatory disorders, announced positive results from a Phase 1 first-in-human study of EP262, a potent, highly selective small molecule antagonist of MRGPRX2.

Escient Pharmaceuticals announced the presentation of preclinical data in a mouse model of atopic dermatitis related to the company’s EP262 development program at the American Academy of Dermatology annual meeting being held in New Orleans, Louisiana, March 17-21, 2023.

Escient Pharmaceuticals announced the presentation of preclinical data related to the company’s EP262 development program at the American Academy of Allergy, Asthma and Immunology Annual meeting being held in San Antonio, TX, February 24-27, 2023.

Escient Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for EP262, enabling the initiation of a Phase 1 first-in-human study for the company’s second drug candidate to be advanced into clinical development.

Escient Pharmaceuticals, a clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders, today announced the presentation of preclinical data related to the company’s EP262 development program at the 6th GA2LEN Global Urticaria Forum being held in Berlin, Germany, December 7-8, 2022.